Add like
Add dislike
Add to saved papers

Factors associated with the development of neonatal hypoglycemia after antenatal corticosteroid administration: It's all about timing.

OBJECTIVE: We aimed to determine the factors associated with neonatal hypoglycemia among neonates exposed to antenatal corticosteroid (ACS).

METHODS: A retrospective study conducted during 2017-2019 at a tertiary-care center including all neonates delivered between 24-34 weeks of gestation after ACS administration. The primary outcome was neonatal hypoglycemia (<40 mg/dL).

RESULTS: Overall, 362 early preterm neonates, including 205 singletons and 157 twins, were exposed to ACS prior to delivery and constituted the study group. Of them, 275 (76.0%) were exposed to a single ACS course and 87 (24.0%) to an additional rescue ACS course. Neonatal hypoglycemia occurred in 84 (23.2%) neonates. The incidence of neonatal hypoglycemia was significantly higher in those delivered between 24 to 48 hours after ACS administration as compared to those delivered outside of this time interval (10/25, 40.0% vs. 74/337, 21.9%, P=0.049). In multivariate analysis, after adjusting for neonatal birthweight and gestational age, delivery within 24-48 hours after ACS administration was found as the only independent risk factor associated with neonatal hypoglycemia (aOR [95% CI]: 2.41 (1.03, 5.68), P=0.044).

CONCLUSION: Neonatal hypoglycemia occurred in over one fifth of those exposed to ACS, and was independently associated with delivery between 24 to 48 hours after ACS administration.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app